ACTG announces publication of REPRIEVE sub-study in JAMA Network Open, providing insights into cardiovascular disease risk among people living with HIV eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
The AIDS Clinical Trials Group, the largest global HIV research network, today announced the launch of A5386, a phase 1 HIV cure study evaluating two promising therapies.
The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5386, a phase 1 HIV cure study evaluating two promising therapies. A5386 will study whether N-803 (a clinical-stage biologic also called Anktiva?) can control HIV alone or together with combination broadly neutralizing antibodies (bNAbs) after participants stop their antiretroviral therapy (ART) and they are carefully monitored.
E-Mail
Los Angeles, Calif. - The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the addition of two monoclonal antibodies, BMS-986414 and BMS-986413, to the COVID-19 outpatient treatment study, ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. BMS-986414 and BMS-986413 will be administered as subcutaneous injections (shots) given at one visit. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple investigational agents for treating early COVID-19 in a single trial. For information about enrolling in the trial, please visit the study website. Given that prevention and treatment will continue to be an important part of ending the COVID-19 pandemic, it is key that we identify and develop a variety of treatment options, said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles (UCLA). ACTIV-2 is studying a number of different therapeutic approaches, including infusions, shots, pi
May 14, 2021
In the first of a series of “fireside chats” with this year’s honorary degree recipients, the College welcomed DeRay Mckesson ’07 H’21, a Black Lives Matter activist and host of the podcast Pod Save the People, in a virtual conversation moderated by Beth Kowitt ’07, a journalist for Fortune Magazine. Mckesson spoke about his career as an activist and the influence of his Bowdoin education.
Mckesson left his career in teaching to become an activist following the death of Michael Brown at the hands of police in Ferguson, Missouri in 2014. He said the career shift was a “faith thing.”
“One of the reasons why I was able to walk away from my job was, ‘I’m young. I’ve done all the things I wanted to do career-wise, I’ll get another job again,’” Mckesson said. “We don’t always have a chance to [do] work that we think could change the trajectory of people’s lives in this sort of way. And that’s sort of why I made that choice.”